Creatv MicroTech Revenue
Biotechnology Research • 
Travilah, Maryland, United States • 11-20 Employees
Creatv MicroTech revenue & valuation
| Annual revenue | $941,105 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $3,100,000 |
| Total funding | No funding |
Key Contacts at Creatv MicroTech
Cha-Mei Tang
Founder, President, And Ceo
Daniel Adams
Director Of Clinical R&D
Company overview
| Headquarters | 11609 Lake Potomac Drive, Potomac, MD 20854, US |
| Phone number | +13019831650 |
| Website | |
| Keywords | Cancer Diagnostics, Companion Diagnostics For Immunotherapy, Diagnostics To Monitor Treatment Response, Early Detection Of Cancer, Early Detection Of Cancer Recurrence, Early Detection Of Solid Tumors |
| Founded | 2000 |
| Employees | 11-20 |
Creatv MicroTech Email Formats
Creatv MicroTech uses 2 email formats. The most common is {first name} (e.g., john@creatvmicrotech.com), used 60% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name} | john@creatvmicrotech.com | 60% |
{first name}{last name} | johndoe@creatvmicrotech.com | 40% |
About Creatv MicroTech
Creatv MicroTech has two divisions: Creatv Bio and Microfabrication. The company is most focused on Creatv Bio Division, and its mission is to dramatically reduce global cancer mortality. Our innovative LifeTracDx® blood test can detect cancer in the earliest stages before symptoms. It can also confirm whether a patient is responding to treatment and surveils for early signs of recurrence after treatment has finished. Creatv Bio also developed a wide spectrum of cancer diagnostics to improve patient care. Clinical application of this highly sensitive and specific test will improve cancer treatment outcomes. Cancer touches all of us. Almost 40% of Americans develop cancer in their lifetime. Over half of these diagnoses occur after significant progression, in stages 3 and 4, making it difficult to achieve successful therapeutic outcomes. Early detection with high accuracy is needed for all major cancers. Nearly 18 million Americans are living with a history of cancer, many in remission under surveillance for possible recurrence. Early detection of recurrence enables faster response and improved outcomes. LifeTracDx® liquid biopsy platform uncovered a previously unknown cell in the blood of cancer patients, the cancer associated macrophage-like cell (CAML). These cells are very large and distinctly different from normal cells and circulating tumor cells (CTCs). CAMLs are found in patients with cancer, but not in healthy individuals. CAMLs are highly informative, because they contain markers of the cancer type and indicate sensitivity or resistance to particular treatments. Unlike CTCs, CAMLs are found in all stages of cancer, including stage I. Together, CAMLs and CTCs provide a unique capability for early detection of cancer, monitoring treatment, and watching for recurrence. LifeTracDx® will be available in a CLIA lab by the beginning of the second quarter of 2025.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Creatv MicroTech has 5 employees across 2 departments.
Departments
Number of employees
Funding Data
Creatv MicroTech has never raised funding before.
Creatv MicroTech Tech Stack
Discover the technologies and tools that power Creatv MicroTech's digital infrastructure, from frameworks to analytics platforms.
Font scripts
JavaScript libraries
JavaScript libraries
Development
Ecommerce
Security
Analytics
Hosting
JavaScript frameworks
Security
Miscellaneous
JavaScript libraries
Italy
Brazil
Singapore
Poland
United Kingdom
Israel
Frequently asked questions
4.8
40,000 users
